GLOBAL BIOSIMILAR DRUG MARKET 2019 BY MANUFACTURERS, REGIONS, TYPE AND APPLICATION, FORECAST TO 2024

Mar 2019 124

Delivery of the Report will take 2-3 working days once order is placed.

Synopsis

Biosimilar drug is medicine made using a living system, and historically this was often an animal. Most products being developed as biosimilar drug are recombinant proteins, or proteins derived from genetically engineered DNA. In this report is a biologic defined as proteins, peptides, hormones or antibodys drugs production by bio-engineered technology, but does not include a vaccine.

Scope of the Report:
As healthcare costs continue to rise, biosimilars offer new therapeutic options with the potential for cost savings to the healthcare system. With anticipated savings, biosimilars bring hope that there will be expanded access for patients to not only these known therapies, but also to new innovative medicines. At Amgen, serving patients is at the core of what we do and it is why we’re using our more than 35 years of biologics experience to develop high-quality biosimilars.

First, in pharmerging markets, both governments and patients struggle to pay for biosimilars, which encouraged the demand of biosimilars, therefore in the future the biosimilars will grow around 20%.

Second, generally, biosimilars industry is still in their infancy in China. It is commonly believed that the next 10 to 15 years is the golden period of the development of biosimilars.

Third, for the biosimilars industry, technical barriers will be much smaller, in the next few years, there will be more and more enterprises going into biosimilars industry.

Forth, most of biosimilars manufacturer are concentrated in US, Germany, UK and other developed countries.

At last, through the research we tend to believe that the biosimilars, now is a chance for newcomers and they will greatly change the industry.

The worldwide market for Biosimilar Drug is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2024, from xx million US$ in 2019, according to a new GIR (Global Info Research) study.
This report focuses on the Biosimilar Drug in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.

Market Segment by Manufacturers, this report covers
- Amgen
- Eli Lilly
- Novartis
- CP Guojian Pharma
- Biotech Pharma

Market Segment by Regions, regional analysis covers
- North America (United States, Canada and Mexico)
- Europe (Germany, France, UK, Russia and Italy)
- Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
- South America (Brazil, Argentina, Colombia etc.)
- Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Market Segment by Type, covers
- Injection
- Tablets
- Other Types

Market Segment by Applications, can be divided into
- Ankylosing Spondylitis
- Tumor
- Rheumatoid Arthrtis
- Cardiovascular
- Other Application

The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Biosimilar Drug product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Biosimilar Drug, with price, sales, revenue and global market share of Biosimilar Drug in 2017 and 2018.
Chapter 3, the Biosimilar Drug competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Biosimilar Drug breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2014 to 2019.
Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2014 to 2019.
Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2014 to 2019.
Chapter 12, Biosimilar Drug market forecast, by regions, type and application, with sales and revenue, from 2019 to 2024.
Chapter 13, 14 and 15, to describe Biosimilar Drug sales channel, distributors, customers, research findings and conclusion, appendix and data source.

Table of Contents

Related reports :

(Dec 19)

Description Scope of the Report: The worldwide market for Midecamycin (CAS 35457-80-8) is expected to grow at a CAGR of roughl...

(Dec 19)

Description Scope of the Report: The worldwide market for Amikacin (CAS 37517-28-5) is expected to grow at a CAGR of roughly x...

(Dec 19)

Description Scope of the Report: The worldwide market for Gentamycin Sulfate (CAS 1405-41-0) is expected to grow at a CAGR of ...

(Dec 19)

Description Scope of the Report: The worldwide market for Neomycin (CAS 119-04-0) is expected to grow at a CAGR of roughly xx%...

(Dec 19)

Description Scope of the Report: The worldwide market for Oxytetracycline (CAS 79-57-2) is expected to grow at a CAGR of rough...

(Dec 19)

Description Scope of the Report: The worldwide market for Diphenyl Azidophosphate (CAS 26386-88-9) is expected to grow at a CA...

GLOBAL BIOSIMILAR DRUG MARKET 2019 BY MANUFACTURERS, REGIONS, TYPE AND APPLICATION, FORECAST TO 2024

Global Info Research

Share this report on:

Subscription Option


Using our subscription option, you get access to Market Research Reports and industry data of Medicine and Pharmacy market as per your needs. Get the best of Medicine and Pharmacy research reports by utilizing your research budgets in an optimum way. Contact for details

Contact for reports

*

We use cookies to deliver the best possible experience on our website.
By continuing to use this site, or closing this box, you consent to our use of cookies. To learn more, visit our Privacy Policy